Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,271.50 -6.01 (-0.11%) Dow
38,441.18 -245.14 (-0.63%) Nasdaq
16,803.96 +68.95 (+0.41%) Bitcoin USD
69,238.60 +1,184.17 (+1.74%) CMC Crypto 200
1,489.89 +21.96 (+1.50%)
TEVA Jan 2025 18.000 call
| Previous close | 1.8700 |
| Open | 1.9000 |
| Bid | 1.8300 |
| Ask | 1.9000 |
| Strike | 18.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.8400 - 2.0100 |
| Contract range | N/A |
| Volume | |
| Open interest | 9.71k |
Business WireNew Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEL AVIV, Israel & PARSIPPANY, N.J., June 01, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia
Business WireTeva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
TEL AVIV, Israel & PARSIPPANY, N.J., June 01, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional impact on patients’ quality of life. These interim findings from the IMPACT-TD study were presented at the 2024 Psych Congress Elevate Annual Meeting, taking place from May 30 –
Business WireTeva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
TEL AVIV, Israel & PARSIPPANY, N.J., May 29, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO XR as a one pill, once-daily treatment option, now with four new tablet strengths (30, 36, 42, 48 mg) indicated in adults for TD and HD chorea.
